Your browser doesn't support javascript.
loading
The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer.
Ghaddar, Nour; Wang, Shuo; Woodvine, Bethany; Krishnamoorthy, Jothilatha; van Hoef, Vincent; Darini, Cedric; Kazimierczak, Urszula; Ah-Son, Nicolas; Popper, Helmuth; Johnson, Myriam; Officer, Leah; Teodósio, Ana; Broggini, Massimo; Mann, Koren K; Hatzoglou, Maria; Topisirovic, Ivan; Larsson, Ola; Le Quesne, John; Koromilas, Antonis E.
Afiliação
  • Ghaddar N; Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, Canada.
  • Wang S; Division of Experimental Medicine, Department of Medicine, Faculty of Medicine, McGill University, Montreal, QC, Canada.
  • Woodvine B; Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, Canada.
  • Krishnamoorthy J; Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
  • van Hoef V; MRC Toxicology Unit, University of Cambridge, Leicester, UK.
  • Darini C; Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, Canada.
  • Kazimierczak U; Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institute, Solna, Sweden.
  • Ah-Son N; Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, Canada.
  • Popper H; Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, Canada.
  • Johnson M; Department of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
  • Officer L; Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, Canada.
  • Teodósio A; Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
  • Broggini M; Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, Canada.
  • Mann KK; Division of Experimental Medicine, Department of Medicine, Faculty of Medicine, McGill University, Montreal, QC, Canada.
  • Hatzoglou M; MRC Toxicology Unit, University of Cambridge, Leicester, UK.
  • Topisirovic I; MRC Toxicology Unit, University of Cambridge, Leicester, UK.
  • Larsson O; Laboratory of Molecular Pharmacology IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
  • Le Quesne J; Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, Canada.
  • Koromilas AE; Gerald Bronfman Department of Oncology, Faculty of Medicine, McGill University, Montreal, QC, Canada.
Nat Commun ; 12(1): 4651, 2021 07 30.
Article em En | MEDLINE | ID: mdl-34330898
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Fator de Iniciação 2 em Eucariotos / Proteínas Proto-Oncogênicas p21(ras) / Fosfatase 6 de Especificidade Dupla / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Fator de Iniciação 2 em Eucariotos / Proteínas Proto-Oncogênicas p21(ras) / Fosfatase 6 de Especificidade Dupla / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá